Cancer Council Australia Melanoma Guidelines Working Party, Sydney, NSW, Australia.
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1290-1298. doi: 10.1111/jdv.17154. Epub 2021 Mar 3.
Desmoplastic melanomas are uncommon. Their behaviour differs from that of other melanoma subtypes; therefore, management guidelines for non-desmoplastic melanomas may not be applicable. This review sought to examine all available evidence relating to the behaviour and management of desmoplastic melanomas, based on review of all relevant English-language publications, and to critically assess the recommendations for their management in current published melanoma management guidelines. Compared with other melanoma subtypes, patients with 'pure' desmoplastic melanomas (where ≥90% of the invasive melanoma is of desmoplastic melanoma subtype) have much lower rates of sentinel node positivity and distant metastasis. Local recurrence rates are higher for desmoplastic melanomas, but resection margins wider than those recommended for non-desmoplastic melanomas have not been shown to be of benefit. Adjuvant radiotherapy reduces the risk of local recurrence when a satisfactory histological clearance (≥8 mm) cannot be achieved. Of 29 published melanoma management guidelines identified, only 11 specified management for desmoplastic melanomas, while seven simply stated that the feature should be reported. Desmoplastic melanoma is a unique melanoma subtype with biology that differs from that of other melanoma subtypes. It requires specific management strategies but few current guidelines address these.
促结缔组织增生性黑色素瘤较为少见。其生物学行为与其他黑色素瘤亚型不同,因此,非促结缔组织增生性黑色素瘤的管理指南可能并不适用。本综述旨在根据所有相关的英文文献,对促结缔组织增生性黑色素瘤的行为和管理的所有现有证据进行审查,并对目前发表的黑色素瘤管理指南中关于其管理的建议进行批判性评估。与其他黑色素瘤亚型相比,“纯”促结缔组织增生性黑色素瘤(≥90%的侵袭性黑色素瘤为促结缔组织增生性黑色素瘤亚型)患者前哨淋巴结阳性和远处转移的发生率要低得多。促结缔组织增生性黑色素瘤的局部复发率较高,但尚未证明切除边缘宽于非促结缔组织增生性黑色素瘤推荐的边缘有利于降低局部复发率。当无法达到满意的组织学清除(≥8 毫米)时,辅助放疗可降低局部复发的风险。在所确定的 29 份发表的黑色素瘤管理指南中,只有 11 份规定了促结缔组织增生性黑色素瘤的管理方法,而 7 份只是简单地指出应报告该特征。促结缔组织增生性黑色素瘤是一种独特的黑色素瘤亚型,其生物学行为与其他黑色素瘤亚型不同。它需要特定的管理策略,但目前很少有指南涉及这些策略。